The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.
Spencer AJ, Morris S, Ulaszewska M, Powers C, Kailath R, Bissett C, Truby A, Thakur N, Newman J, Allen ER, Rudiansyah I, Liu C, Dejnirattisai W, Mongkolsapaya J, Davies H, Donnellan FR, Pulido D, Peacock TP, Barclay WS, Bright H, Ren K, Screaton G, McTamney P, Bailey D, Gilbert SC, Lambe T.
Spencer AJ, et al. Among authors: mongkolsapaya j.
EBioMedicine. 2022 Mar;77:103902. doi: 10.1016/j.ebiom.2022.103902. Epub 2022 Feb 26.
EBioMedicine. 2022.
PMID: 35228013
Free PMC article.